Sokolova E - Search Results

1

HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis.

Sokolova E, Guryev E, Yudintsev A, Vodeneev V, Deyev S, Balalaeva I. Sokolova E, et al. Oncotarget. 2017 Mar 28;8(13):22048-22058. doi: 10.18632/oncotarget.15833. Oncotarget. 2017. PMID: 28423549 Free PMC article.

2

HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model.

Sokolova EA, Shilova ON, Kiseleva DV, Schulga AA, Balalaeva IV, Deyev SM. Sokolova EA, et al. Int J Mol Sci. 2019 May 15;20(10):2399. doi: 10.3390/ijms20102399. Int J Mol Sci. 2019. PMID: 31096563 Free PMC article.

3

A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins.

Zdobnova T, Sokolova E, Stremovskiy O, Karpenko D, Telford W, Turchin I, Balalaeva I, Deyev S. Zdobnova T, et al. Among authors: sokolova e. Oncotarget. 2015 Oct 13;6(31):30919-28. doi: 10.18632/oncotarget.5130. Oncotarget. 2015. PMID: 26436696 Free PMC article.

4

Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo.

Sokolova E, Proshkina G, Kutova O, Shilova O, Ryabova A, Schulga A, Stremovskiy O, Zdobnova T, Balalaeva I, Deyev S. Sokolova E, et al. J Control Release. 2016 Jul 10;233:48-56. doi: 10.1016/j.jconrel.2016.05.020. Epub 2016 May 10. J Control Release. 2016. PMID: 27178808

5

Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency.

Sokolova EA, Zdobnova TA, Stremovskiy OA, Balalaeva IV, Deyev SM. Sokolova EA, et al. Biochemistry (Mosc). 2014 Dec;79(12):1376-81. doi: 10.1134/S0006297914120128. Biochemistry (Mosc). 2014. PMID: 25716732 Free article.

6

3D in vitro models of tumors expressing EGFR family receptors: a potent tool for studying receptor biology and targeted drug development.

Sokolova EA, Vodeneev VA, Deyev SM, Balalaeva IV. Sokolova EA, et al. Drug Discov Today. 2019 Jan;24(1):99-111. doi: 10.1016/j.drudis.2018.09.003. Epub 2018 Sep 8. Drug Discov Today. 2019. PMID: 30205170 Review.

7

Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug, Doxorubicin.

Sokolova E, Kutova O, Grishina A, Pospelov A, Guryev E, Schulga A, Deyev S, Balalaeva I. Sokolova E, et al. Pharmaceutics. 2019 May 7;11(5):219. doi: 10.3390/pharmaceutics11050219. Pharmaceutics. 2019. PMID: 31067739 Free PMC article.

8

Far-red fluorescent cell line for preclinical study of HER2-targeted agents.

Balalaeva IV, Sokolova EA, Brilkina AA, Deyev SM, Petrov RV. Balalaeva IV, et al. Among authors: sokolova ea. Dokl Biochem Biophys. 2015;465:410-2. doi: 10.1134/S1607672915060174. Epub 2016 Jan 5. Dokl Biochem Biophys. 2015. PMID: 26728737

9

Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors.

Sokolova EA, Stremovskiy OA, Zdobnova TA, Balalaeva IV, Deyev SM. Sokolova EA, et al. Acta Naturae. 2015 Oct-Dec;7(4):93-6. Acta Naturae. 2015. PMID: 26798495 Free PMC article.

10

Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro.

Balalaeva IV, Sokolova EA, Puzhikhina AD, Brilkina AA, Deyev SM. Balalaeva IV, et al. Among authors: sokolova ea. Acta Naturae. 2017 Jan-Mar;9(1):38-43. Acta Naturae. 2017. PMID: 28461972 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

477 results

Search Page

Filters